fbpx Interview with Professor José Alberto Del Porto, Sao Paulo, Brazil | Progress In Mind

Interview with Professor José Alberto Del Porto, Sao Paulo, Brazil

Interview with professor about depression.

Professor José Del Porto of the EPM-UNIFESP describes the challenges and new developments in the management of patients with mood disorders.
What are the most significant challenges facing clinicians today when treating mood disorders?

Regarding mood disorders, I think one of the most important issues is accurate diagnosis, because currently we do not have biological markers and have to rely on clinical observation of symptoms and syndromes.

It is also important to distinguish between bipolar and unipolar depression.

Depression is a major health problem all over the world and it has a significant impact clinically and economically – impairing daily and social function as well as work function. Along with alcohol use and bipolar disorder it is one of the most impactful and important public health issues today.

How would you define remission?

Our goal, in every case, must be to achieve total remission – and not just remission of symptoms  –  but also remission that ensures a complete return to the level of function that the patient had before the disease.

By that I mean social function and work function, as well as restoring pleasure in activities.

Otherwise there is a risk of recurrence, a risk of chronification and a risk for comorbid conditions like alcohol consumption and cardiovascular diseases. So our goal must be a total remission. I think that is achievable in most cases if we treat early with the right therapies or combination of treatments.

The more the disease recurs, the harder it may become to achieve total remission. There is more chronification, more recurrence and more complications like cognitive impairment.

What types of tools do you use regularly in your daily practice?

I personally like to use the Hamilton scale, the Montgomery-Åsberg scale, and I often ask my patients to complete a screening tool to identify hypomanic symptoms because this is very important to distinguish bipolar from unipolar depression. So we use the hypomania checklist. I also use an ability scale to measure any impairment in the social, work and family function. This is important when we are seeking to achieve the total remission and total return to functioning I was describing.  

Do you look for cognitive symptoms in depressed patients and if so, how?

Cognitive function in depression has been a neglected area. Depression is a very complex syndrome, involving not only mood but affecting cognitive function. Until recently, we didn’t have instruments to assess cognition easily in the office. So if I had a patient with a complicated cognitive picture, I had to send them to the psychologist for an assessment of neurocognitive function.

Fortunately, we now have an easy instrument that has been developed to allow us to assess cognitive function and I find it is very easy to apply and think it will prove to be a very useful tool to use in the future in our clinical settings.

What have been the most significant advances in the field of depression research recently?

In recent years we have seen subtypes of serotinergic receptors identified – like 5HT7 -  and there has been research on glutaminergic functioning  - and this type of basic research has opened the way for more impactful drug treatments that may help with cognitive function.

You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente ai Professionisti Sanitari. I contenuti di questo sito sono prodotti da un team dedicato di Professionisti Sanitari e medical writer il cui obiettivo è presentare le novità scientifiche più recenti insieme ad opinioni di esperti ed approfondimenti in ambito psichiatrico e neurologico. Per poter accedere al sito è, quindi, necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Professionista Sanitario.
Per accedere alla pagina si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi. La pagina per la quale sta richiedendo l'accesso ospita materiale formativo comunque attinente all'impiego di medicinali prodotti o commercializzati da Lundbeck. Con riferimento al Decreto Legislativo n.219 del 24 aprile 2006 e s.m.i., art. 119, art. 121 comma 1 e art. 124 commi 4 e 8, Lundbeck limita l'accesso ai contenuti presenti nella pagina PIM Academy a medici specialisti e farmacisti ospedalieri.
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country